✓ Fulfilled in the USA
✓ Batch Produced & Tested
✓ Fast & Discreet Shipping
✓ >99% Purity Guaranteed
✓ COA Every Batch
✓ Independently Tested
✓ 24/7 Support
✓ Fulfilled in the USA
✓ Batch Produced & Tested
✓ Fast & Discreet Shipping
✓ >99% Purity Guaranteed
✓ COA Every Batch
✓ Independently Tested
✓ 24/7 Support
✓ Fulfilled in the USA
✓ Batch Produced & Tested
✓ Fast & Discreet Shipping
✓ >99% Purity Guaranteed
✓ COA Every Batch
✓ Independently Tested
✓ 24/7 Support

IGF-1 LR3 Nasal Spray

$1.00

CAS #: 946870-92-4
Formula: C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉
M.W.: 9117.60 g/mol

Description

Product Overview

IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) is an 83-amino-acid polypeptide analog of human IGF-1. It features a 13-amino-acid N-terminal extension and an arginine substitution at position three of the original IGF-1 sequence. Preclinical studies have examined its receptor-binding properties, IGF-related signaling pathways, and cellular responses. Its safety, effectiveness, and nasal bioavailability have not been established for this formulation.

Product Specifications

Specification

Details

Product Name

IGF-1 LR3 Nasal Spray

Total Content

To Be Confirmed (mg TBC)

Product Format

Nasal Spray Bottle

Compound Type

Synthetic Growth Factor Analog

CAS Number

143045-27-6

Molecular Formula

C₄₀₀H₆₁₉N₁₁₁O₁₁₅S₉

Molecular Weight

Approximately 9,111.5 Da

Amino Acid Length

83 Amino Acids

Bottle Volume

Manufacturer confirmation required

Research Applications

IGF-1 receptor signaling studies

Growth factor interaction research

Cellular signaling pathway investigations

Storage & Handling

Follow the manufacturer's validated storage and handling instructions for the liquid nasal spray formulation.

Disclaimer

For Research Use Only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. Nasal administration safety and effectiveness have not been established.

Reviews

There are no reviews yet.

Be the first to review “IGF-1 LR3 Nasal Spray”

Your email address will not be published. Required fields are marked *